Literature DB >> 7979292

Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia.

P M Roblin1, G Montalban, M R Hammerschlag.   

Abstract

We tested in vitro 49 isolates of Chlamydia pneumoniae obtained from 35 children with community-acquired pneumonia against clarithromycin and erythromycin. The children were part of a treatment study comparing the two drugs. Clarithromycin was 2- to 10-fold more active than erythromycin, with a MIC for 90% of strains tested and minimal chlamydiacidal concentration for 90% of strains tested of 0.031 microgram/ml compared with 0.125 microgram/ml for erythromycin. Eight of these children, two of whom were treated with erythromycin and six of whom received clarithromycin, remained culture positive after treatment. We were able to test 21 isolates from these children. All were susceptible to both drugs, and the MICs did not change after therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979292      PMCID: PMC284597          DOI: 10.1128/AAC.38.7.1588

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics.

Authors:  R B Jones; B Van der Pol; D H Martin; M K Shepard
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

2.  Persistent infection with Chlamydia pneumoniae following acute respiratory illness.

Authors:  M R Hammerschlag; K Chirgwin; P M Roblin; M Gelling; W Dumornay; L Mandel; P Smith; J Schachter
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

Review 3.  A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston; L A Campbell; C C Kuo; C H Mordhorst; P Saikku; D H Thom; S P Wang
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

4.  Relative resistance to erythromycin in Chlamydia trachomatis.

Authors:  A Mourad; R L Sweet; N Sugg; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

5.  In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; K K Qumei; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

6.  The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans.

Authors:  F Fraschini; F Scaglione; G Pintucci; G Maccarinelli; S Dugnani; G Demartini
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

7.  A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections.

Authors:  J T Grayston; C C Kuo; S P Wang; J Altman
Journal:  N Engl J Med       Date:  1986-07-17       Impact factor: 91.245

  7 in total
  18 in total

1.  In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.

Authors:  S Strigl; P M Roblin; T Reznik; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 2.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

3.  Chlamydia pneumoniae resists antibiotics in lymphocytes.

Authors:  Hiroyuki Yamaguchi; Herman Friedman; Mayumi Yamamoto; Keigo Yasuda; Yoshimasa Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

4.  Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.

Authors:  Paul F Riska; Andrei Kutlin; Patrick Ajiboye; Arnold Cua; Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

5.  In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.

Authors:  Patricia M Roblin; Stephan A Kohlhoff; Charles Parker; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

Review 6.  Chlamydiae as pathogens: new species and new issues.

Authors:  R W Peeling; R C Brunham
Journal:  Emerg Infect Dis       Date:  1996 Oct-Dec       Impact factor: 6.883

Review 7.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors:  H D Langtry; R N Brogden
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 8.  Asthma in children: are chlamydia or mycoplasma involved?

Authors:  S Esposito; N Principi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

9.  Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors:  Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae.

Authors:  J Gnarpe; K Eriksson; H Gnarpe
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.